Compare Amgen, Inc. (AMGN) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs General Dynamics Corporation — how do they compare? Amgen, Inc. trades at $356.22 (market cap $196.12B), while General Dynamics Corporation trades at $372.53 (market cap $101.43B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | GD | |
|---|---|---|
Market Cap | $196.12B | $101.43B |
Sector | Health | Industrials |
52-Week High | $388.16 | $376.88 |
52-Week Low | $271.18 | $297.05 |
Enterprise Value | $241.41B | $107.61B |
Dividend Yield | 2.77% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
General Dynamics (GD) trades at $375.06, up 0.12% today, near its 52-week high with strong technical momentum. The stock shows robust fundamentals, including consistent earnings beats, revenue growth to $52.55B in 2025, and healthy margins. Analyst sentiment is bullish, with a consensus price target of $395.83, supported by a backlog surge to $130.8B in Q1 2026 (Seeking Alpha, 2026-07-02).
Outlook remains positive due to defense spending tailwinds and submarine contract wins, but risks include execution delays and valuation concerns. The stock offers growth potential with a 5.6% upside to consensus target, though high RSI levels suggest near-term overbought conditions. Investors should weigh strong cash flow and dividend stability against geopolitical and supply chain uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
